Grivas, Petros
Yu, Evan Y.
Article History
First Online: 28 June 2019
Compliance with Ethical Standards
:
: Petros Grivas has received research funding (paid to Cleveland Clinic Foundation for conduction of clinical trials) from Genentech, Bayer, Merck & Co., Mirati Therapeutics, OncoGenex Pharmaceuticals, Pfizer, and AstraZeneca; has received research funding (paid to the University of Washington for conduction of clinical trials) from Pfizer, Clovis Oncology, Bavarian Nordic, and Immunomedics; has received compensation from Genentech, Dendreon, Bayer, Merck & Co., Pfizer, Bristol-Myers Squibb, Exelixis, AstraZeneca, Biocept, Clovis Oncology, EMD Serono, Seattle Genetics, Foundation Medicine, Driver, Inc., QED Therapeutics, Heron Therapeutics, and Janssen; and has participated in educational, unbranded, non-product-related speaker’s program (after providing direct input for content of slides) sponsored by Genentech and Bristol-Myers Squibb.Evan Y. Yu has received research funding from Bayer, Dendreon, Merck, and Seattle Genetics and has received compensation from Amgen, AstraZeneca, Bayer, Churchill Pharmaceuticals, Dendreon, EMD Serono, Incyte Corporation, Janssen, Merck, Pharmacyclics, QED Therapeutics, Tolmar, Inc., and Seattle Genetics for service as a consultant.
: This article does not contain any studies with human or animal subjects performed by any of the authors.